Telix Pharmaceuticals (NASDAQ:TLX) Sets New 1-Year Low – Time to Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $8.68 and last traded at $8.66, with a volume of 53394 shares trading hands. The stock had previously closed at $9.03.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on TLX shares. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. UBS Group cut their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada assumed coverage on shares of Telix Pharmaceuticals in a report on Monday. They issued a “sector perform” rating on the stock. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Trading Down 4.7%

The company has a 50-day moving average of $9.98 and a 200-day moving average of $12.15.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its stake in Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the period. IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at approximately $213,000. Blair William & Co. IL bought a new position in Telix Pharmaceuticals in the 2nd quarter worth approximately $217,000. JPMorgan Chase & Co. purchased a new position in Telix Pharmaceuticals in the 3rd quarter valued at approximately $243,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.